Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 By Investing.com

Scott Bizily, Chief Legal Officer at 4D Molecular Therapeutics, Inc. (), recently sold shares worth $8,176 after exercising stock options, according to a Form 4 filing with the Securities and Exchange Commission.

On September 1, 2026, Mr. Bizily acquired 584 shares of common stock by exercising options at a price of $6.49 per share, totaling $3,790. On the same day, he sold these 584 shares for $14.0 per share, amounting to a total of $8,176. These transactions were conducted under a pre-arranged 10b5-1 trading plan, which was adopted on January 13, 2026.The stock currently trades at $14.70, with shares delivering a 122% return over the past year. According to InvestingPro analysis, FDMT appears undervalued relative to its Fair Value, placing it among opportunities on the most undervalued stocks list. InvestingPro subscribers have access to 15 additional exclusive tips and comprehensive financial metrics for deeper analysis.

Following these transactions, Mr. Bizily directly holds 8,617 shares of 4D Molecular Therapeutics common stock. He also directly holds options to buy an additional 2,959 shares. The shares underlying the stock option award vest over time, with full vesting occurring on the fourth anniversary of the June 16, 2022 vesting commencement date, provided the grantee remains a service provider to the company.

In other recent news, 4D Molecular Therapeutics has been in the spotlight with several key developments. The company is advancing its pivotal Phase 3 trials for the 4D-150 gene therapy, with the 4FRONT-1 trial in North America and the 4FRONT-2 global trial, both making significant progress. H.C. Wainwright reiterated a Buy rating on the stock, maintaining a $36 price target, following positive two-year data from the Phase 2b PRISM trial. This trial evaluated 4D-150, a promising gene therapy candidate for wet age-related macular degeneration. B.Riley also initiated coverage with a Buy rating, setting a price target of $37, citing the de-risked nature of the 4D-150 candidate in ongoing Phase 3 studies. Additionally, 4D Molecular Therapeutics held its 2026 Annual Meeting of Stockholders, where three Class III director nominees were elected to the board. These developments indicate continued progress and interest from analysts in the company’s ongoing projects and governance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.